Article
A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer‐Related Germline Mutations
2 Mar 2018
Abstract excerpt
The rapid drop in the cost of DNA sequencing led to the availability of multi-gene panels, which test 25 or more cancer susceptibility genes for a low cost. Clinicians and genetic counselors need a tool to interpret results, understand risk of various cancers, and advise on a management strategy. This is challenging as there are multiple studies regarding each gene, and it is not possible for clinicians and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
